Securian Asset Management Inc. Sells 40,585 Shares of Kenvue Inc. $KVUE

Securian Asset Management Inc. cut its stake in Kenvue Inc. (NYSE:KVUE) by 43.8% in the fourth quarter, HoldingsChannel reports. The fund owned 52,094 shares of the company’s stock after selling 40,585 shares during the period. Securian Asset Management Inc.’s holdings in Kenvue were worth $899,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Physician Wealth Advisors Inc. grew its stake in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the last quarter. Cornerstone Planning Group LLC raised its position in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares during the last quarter. NBT Bank N A NY lifted its holdings in Kenvue by 180.3% during the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after buying an additional 1,006 shares in the last quarter. Golden State Wealth Management LLC boosted its position in Kenvue by 150.1% in the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after buying an additional 1,190 shares during the last quarter. Finally, SBI Securities Co. Ltd. boosted its position in Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after buying an additional 1,027 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.59% of the company’s stock.

Kenvue Stock Down 1.5%

Shares of NYSE KVUE opened at $17.22 on Thursday. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $24.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.68 and a current ratio of 0.98. The stock has a market cap of $33.05 billion, a P/E ratio of 20.25, a P/E/G ratio of 1.33 and a beta of 0.55. The firm has a 50 day moving average price of $17.52 and a 200 day moving average price of $17.30.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period last year, the business posted $0.24 earnings per share. Analysts expect that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th will be paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.8%. The ex-dividend date of this dividend is Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is presently 97.65%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Citigroup dropped their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, April 15th. Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the company from $23.00 to $18.00 in a report on Friday, January 30th. Barclays lowered their price objective on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. UBS Group cut their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 7th. Finally, Argus raised shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.